aTyr Pharma, Inc.(US:ATYR) Prnewswire·2025-11-14 14:00Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between November 7, 2024, and September 12, 2025 [1][2] - The lawsuit claims that aTyr provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - The stock price of aTyr dropped significantly by 83.2%, from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint [2] Class Action Details - Investors who suffered losses during the specified timeframe can request to be appointed as lead plaintiff by December 8, 2025 [3] - Participation in the class action does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]